Indian Drug Firm Jubilant Collaborates With Cyclopharm to Market Technegas in the US

Technegas, an imaging agent primarily used in Pulmonary Embolism(blockage of lung arteries)is currently sold in 55 countries like EU, Japan and Canada by CYC.

Jubilant Life Sciences subsidiary Jubilant DraxImage Inc has signed a deal with Australia's Cyclopharm to market Technegas, an imaging agent primarily used in Pulmonary Embolism (blockage of lung arteries).

Jubilant said, “Its wholly-owned //subsidiary Jubilant DraxImage Inc has signed a term sheet, subject to satisfactory due diligence and execution of the Definitive Agreement and other necessary approvals, with Cyclopharm Ltd providing DraxImage an exclusive license to market and distribute Technegas in the United States".

Indian Pharma Gets USFDA Approval To Market Tablets To Treat Osteoporosis In The US
The approval for Aurobindo Pharma’s Raloxifene Hydrochloride tablets is for strength of 60 mg that is therapeutically equivalent to Evista, 60 mg of Eli Lilly.

"DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain USFDA approval," it added.

Jubilant Life Sciences Chairman Shyam S Bhartia and CoChairman and Managing Director Hari S Bhartia said, "We are pleased to partner with CYC for the clinical development and potential US market introduction of Technegas. This partnership reiterates our commitment to add innovative products in our Radiopharmaceuticals portfolio and will leverage our existing strengths in the nuclear imaging business."

The company said DraxImage will provide at risk up to $4.5 million to fund the USFDA clinical trial currently under development with any additional costs to be funded by both parties equally.

EarlySense Partners With Beurer to Market Contact-Free Sleep and Wellness Sensor
The ‘SE 80 SleepExpert’ communicates with a dedicated smartphone app to provide valuable information, including heart rate, respiratory rate, and body motion.

"Upon successful completion of the USFDA trial, DraxImage will be able to convert USFDA trial costs into CYC common stock up to a maximum of 15 percent of the total CYC shareholding," it said.

"DraxImage will pay CYC a 17.5 percent royalty on sale in addition to an agreed margin above the cost of goods sold," it added. At present, Technegas is being sold in 55 countries including EU, Japan and Canada by CYC.

Indian Pharma Recalls Its Drugs To Treat Blood Pressure And Cholesterol From The US Market
Dr Reddy's Laboratories is recalling Amlodipine besylate and Atorvastatin calcium tablets in strengths including 2.5mg/10mg, 2.5 mg/20mg and 10mg /80mg.

Source-PTI

Generics To Account For 85% Share in the Domestic Pharma Market By 2020
India is likely to be among the top three pharmaceutical markets globally by incremental growth and the sixth largest in absolute size.